European Journal of Surgical Oncology
Volume 35, Issue 1 , Pages 25-31 , January 2009

Axillary recurrence rate after tumour negative and micrometastatic positive sentinel node procedures in breast cancer patients, a population based multicenter study

  • C.S.E. Bulte

      Affiliations

    • Department of Surgical Oncology, University Medical Centre Utrecht, Postbus 85500, 3508 GA Utrecht, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 6 19912486; fax: +31 30 2505459.
    • ,
  • M. van der Heiden-van der Loo

      Affiliations

    • Comprehensive Cancer Centre Middle Netherlands, Postbus 19079, 3501 DB Utrecht, The Netherlands
    • ,
  • A. Hennipman

      Affiliations

    • Department of Surgical Oncology, University Medical Centre Utrecht, Postbus 85500, 3508 GA Utrecht, The Netherlands

,Accepted 2 June 2008.

References 

  1. Naik AM, Fey J, Gemignani M, et al. The risk of axillary relapse after sentinel node biopsy for breast cancer is comparable with that of axillary lymph node dissection. Ann Surg. 2004;240:462–468
  2. Celebioglu F, Frisell J, Danielsson R, Bergkvist L. Sentinel node biopsy in non-palpable breast cancer and in patients with a previous diagnostic excision. Eur J Surg Oncol. 2007;33:276–280
  3. Palesty JA, Foster JM, Hurd TC, Watroba N, Rezaishiraz H, Edge SB. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer. J Surg Oncol. 2006;93:129–132
  4. Giuliano AE, Haigh PI, Brennan MB, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000;18:2553–2559
  5. Veronesi U, Paganelli G, Viale G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7:983–990
  6. Burak WE, Hollenbeck ST, Zervos EE, Hock KL, Kemp LC, Young DC. Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am J Surg. 2002;183:23–27
  7. Van der Heiden-van der Loo M, Bezemer PD, Hennipman A, et al. Introduction of sentinel node biopsy and stage migration of breast cancer. Eur J Surg Oncol. 2006;32:710–714
  8. Van Deurzen CH, Van Hillegersberg R , Hobbelink MG, Seldenrijk CA, Koelemij R, van Diest PJ. Predictive value of tumor load in breast cancer sentinel lymph nodes for second echelon lymph node metastases. Cell Oncol. 2007;29:497–505
  9. Van Rijk MC, Peterse JL, Nieweg OE, Oldenburg HS, Rutgers EJ, Kroon BB. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes. Cancer. 2006;107:467–471
  10. Querzoli P, Pedriali M, Rindali R, et al. Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. Clin Cancer Res. 2006;12:6696–6701
  11. Kahn HJ, Hanna WM, Chapman WA, et al. Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system. Breast J. 2006;12:294–301
  12. Nationaal Borstkanker Overleg Nederland . Richtlijn behandeling mammacarcinoom. Amsterdam: NABON; 2002;
  13. Uren RF, Howman-Giles RB, Thompson JF, et al. Mammary lymphoscintigraphy in breast cancer. J Nucl Med. 1995;36:1775–1780
  14. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med. 1998;339:941–946
  15. Roumen RMH, Kuijt GP, Liem IH, van Beek MW. Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissection. Br J Surg. 2001;88:1639–1643
  16. Schrenk P, Hatzl-Griesenhofer M, Shamiyeh A, Waynad W. Follow-up of sentinel node negative breast cancer patients without axillary lymph node dissection. J Surg Oncol. 2001;77:165–170
  17. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–553
  18. Koelliker SL, Chung MA, Mainiero MB, Steinhoff MM, Cady B. Axillary lymph nodes: US guided fine needle aspiration for initial staging of breast cancer—correlation with primary tumour size. Radiology. 2008;246:81–89
  19. Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik A, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?. Ann Surg. 1999;229:536–541
  20. Rydèn L, Chebil G, Sjöström L, Pawlowski R, Jönsson PE. Determination of sentinel lymph node status in primary breast cancer by prospective use of immunohistochemistry increases the rate of micrometastases and isolated tumour cells: analysis of 174 patients after SLN biopsy. Eur J Surg Oncol. 2007;33:33–38
  21. Den Bakker MA, Van Weeszenberg A, de Kanter AY, et al. Non-sentinel lymph node involvement in patients with breast cancer and sentinel node micrometastasis; too early to abandon axillary clearance. J Clin Pathol. 2002;55:932–935
  22. Noguchi M. Avoidance of axillary lymph node dissection in selected patients with node-positive breast cancer. Eur J Surg Oncol. 2007;May 9 (Epub)
  23. Bettelheim R, Price KN, Neville AM. For the International (Ludwig) Breast Cancer Study Group: prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet. 1990;335:1565–1568
  24. Cox C, Vrcel V, Riker A. Significance of sentinel lymph node micrometastasis on survival for patients with invasive breast cancer. Newsletter San Antonio Breast Cancer Symposium. December 10, 2005;Issue 3
  25. Chen SL, Hoehne FM, Giuliano AE. The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis. Ann Surg Oncol. 2007;14:3378–3384
  26. Kuijt GP, Voogd AC, van de Poll-Franse LV, Scheijmans LJ, van Beek MW, Roumen RMH. The prognostic significance of axillary lymph-node micrometastases in breast cancer patients. Eur J Surg Oncol. 2005;31:500–505
  27. Rutgers EJ, Meijnen P, Bonnefoi H. Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res. 2004;6:165–169
  28. Mansel RE, Goyal A. European studies on breast lymphatic mapping. Semin Oncol. 2004;31:304–310
  29. White RL, Wilke LG. Update on the NSABP an ACOSOG breast cancer sentinel node trials. Am Surg. 2004;70:420–424
  30. Voogd AC, Nielsen M, Peterse JH, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19:1688–1697

☆ On behalf of the Surgical Oncology Group of the Comprehensive Cancer Centre Middle Netherlands: R. Koelmij, St. Anthonius Ziekenhuis Nieuwegein, C.I. Perre, Diakonessenhuis Utrecht, J.P. Vente, Hofpoort Ziekenhuis Woerden, G.H.M. Verberne, Meander MC Amersfoort, E.B.M. Theunissen, MESOS MC Utrecht, J.E. Rütter, Rivierenland Ziekenhuis Tiel.

PII: S0748-7983(08)00190-X

doi: 10.1016/j.ejso.2008.06.001

European Journal of Surgical Oncology
Volume 35, Issue 1 , Pages 25-31 , January 2009

Article Tools